Cipla to Fully Acquire Inzpera Healthsciences, Strengthening Focus on Paediatrics and Wellness
Through this acquisition, Cipla reinforces its commitment to improving everyday health outcomes and broadening access to quality, evidence-backed healthcare solutions for children and families across India.
- By Newsdesk
- New Delhi
- Nov 04, 2025
Pharmaceutical giant Cipla Ltd has announced the complete acquisition of Inzpera Healthsciences Ltd, a Mumbai-based firm known for its innovation in paediatric and wellness products. The acquisition, valued at approximately ₹110.65 crore, includes all equity shares and non-convertible redeemable preference shares of Inzpera, bringing its total enterprise value to around ₹120 crore.
Founded in 2016, Inzpera has built a strong presence in the paediatric and wellness segments with a portfolio of differentiated products. For Cipla, this acquisition aligns with its long-term strategy of expanding into high-growth consumer health and wellness spaces beyond its traditional pharmaceutical base. By integrating Inzpera’s specialised offerings with Cipla’s robust distribution network and operational expertise, the company aims to scale its presence in the Indian wellness and paediatric markets.
The transaction is expected to close within a month, subject to customary closing conditions and regulatory approvals.
This move marks another milestone in Cipla’s journey to diversify its business model and tap into emerging healthcare segments. For Inzpera, becoming a wholly owned subsidiary of Cipla opens access to advanced manufacturing capabilities, stronger market reach, and greater investment in product innovation.
Through this acquisition, Cipla reinforces its commitment to improving everyday health outcomes and broadening access to quality, evidence-backed healthcare solutions for children and families across India.